PB 3 of 2011
National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No. 1)
National Health Act 1953
___________________________________________________________________________
I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 26 January 2011
FELICITY MCNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
1 Name of Amendment Instrument
(1) This Instrument is the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No.1).
(2) This Instrument may also be cited as PB 3 of 2011.
2 Commencement
This Instrument commences on 1 February 2011.
3 Amendments to PB 117 of 2010
Schedule 1 amends PB 117 of 2010.
Schedule 1 Amendments
[1] Schedule 1, entries for Doxorubicin – Pegylated Liposomal
omit from the column headed ‘Responsible Person’ (twice occurring):
SH
and insert (twice occurring):
JC
[2] Schedule 1, entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate)
insert in the columns in the order indicated, after “APO-Ondansetron”:
Ondansetron-DRLA
RZ
EMP
C3050
4
0
[3] Schedule 1, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)
insert in the columns in the order indicated, after “APO-Ondansetron”:
Ondansetron-DRLA
RZ
EMP
C3050
4
0
[4] Schedule 2, entry for Code “PL”
omit from the column headed ‘Responsible person’:
Virgo Unit Trust
and insert:
The Trustee for Virgo Unit Trust (trading as Phebra)
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See http://www.frli.gov.au.
